These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32839656)

  • 21. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
    Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
    JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?
    Balcı C; Uzun Ö; Arıcı M; Hayran SA; Yüce D; Ünal S
    Int J Antimicrob Agents; 2018 Aug; 52(2):180-184. PubMed ID: 29649586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression of Kidney Injury with the Combination of Vancomycin and Piperacillin-Tazobactam or Cefepime in Sepsis-Associated Acute Kidney Injury.
    Whitenack K; Behal ML; Thompson Bastin ML; Aycinena JC; Adams PM; Flannery AH
    Front Nephrol; 2022; 2():. PubMed ID: 36507064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
    Rungkitwattanakul D; Ives AL; Harriott NG; Pan-Chen S; Duong L
    J Chemother; 2022 Apr; 34(2):103-109. PubMed ID: 34424136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit.
    Buckley MS; Hartsock NC; Berry AJ; Bikin DS; Richards EC; Yerondopoulos MJ; Kobic E; Wicks LM; Hammond DA
    J Crit Care; 2018 Dec; 48():32-38. PubMed ID: 30172962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The concomitant use of vancomycin and piperacillin-tazobactam is associated with acute kidney injury (AKI) in extremely low birth weight infants (ELBW).
    Al-Jebawi Y; Karalic K; Shekhawat P; Mhanna MJ
    J Neonatal Perinatal Med; 2022; 15(2):303-309. PubMed ID: 34864693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
    Miano TA; Hennessy S; Yang W; Dunn TG; Weisman AR; Oniyide O; Agyekum RS; Turner AP; Ittner CAG; Anderson BJ; Wilson FP; Townsend R; Reilly JP; Giannini HM; Cosgriff CV; Jones TK; Meyer NJ; Shashaty MGS
    Intensive Care Med; 2022 Sep; 48(9):1144-1155. PubMed ID: 35833959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
    Alosaimy S; Lagnf AM; Hobbs ALV; Mubarez M; Kufel WD; Morrisette T; Polisetty RS; Li D; Veve MP; Simon SP; Truong J; Finch N; Venugopalan V; Rico M; Amaya L; Yost C; Cubillos A; Chandler E; Patch M; Smith IMK; Biagi M; Wrin J; Moore WJ; Molina KC; Rebold N; Holger D; Kunz Coyne AJ; Jorgensen SCJ; Witucki P; Tran NN; Davis SL; Sakoulas G; Rybak MJ
    Clin Infect Dis; 2023 Feb; 76(3):e1444-e1455. PubMed ID: 35982631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam versus vancomycin and piperacillin/tazobactam.
    Shao CH; Tai CH; Lin FJ; Wu CC; Wang JT; Wang CC
    J Formos Med Assoc; 2022 Jan; 121(1 Pt 1):117-125. PubMed ID: 33637370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime.
    Quach HT; Esbenshade AJ; Zhao Z; Banerjee R
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27750. PubMed ID: 30989780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study.
    O'Callaghan K; Hay K; Lavana J; McNamara JF
    Int J Antimicrob Agents; 2020 Jul; 56(1):106010. PubMed ID: 32413387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury.
    Aslan AT; Pashayev T; Dağ O; Akova M
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1953-1961. PubMed ID: 33884515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerance and microbiological efficacy of cefepime or piperacillin/tazobactam in combination with vancomycin as empirical antimicrobial therapy of prosthetic joint infection: a propensity-matched cohort study.
    Triffault-Fillit C; Mabrut E; Corbin K; Braun E; Becker A; Goutelle S; Chaudier P; Fessy MH; Dupieux C; Laurent F; Gunst S; Lustig S; Chidiac C; Ferry T; Valour F
    J Antimicrob Chemother; 2020 Aug; 75(8):2299-2306. PubMed ID: 32407512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
    Robertson AD; Li C; Hammond DA; Dickey TA
    Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Kidney Injury in Pediatric Patients Treated with Vancomycin and Piperacillin-Tazobactam Versus Vancomycin and Cefotaxime: A Single-center Study.
    Alqurashi R; Batwa M; Alghamdi B; Aljohani S; Zaher N; Alzahrani A; Aldigs E; Safdar O
    Cureus; 2020 Jan; 12(1):e6805. PubMed ID: 32140363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model.
    He M; Souza E; Matvekas A; Crass RL; Pai MP
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
    Jeon N; Staley B; Klinker KP; Hincapie Castillo J; Winterstein AG
    Int J Antimicrob Agents; 2017 Jul; 50(1):63-67. PubMed ID: 28522340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
    Buhlinger KM; Fuller KA; Faircloth CB; Wallace JR
    Am J Health Syst Pharm; 2019 Aug; 76(16):1204-1210. PubMed ID: 31369115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury.
    Muklewicz JD; Steuber TD; Edwards JD
    Int J Antimicrob Agents; 2021 Jan; 57(1):106234. PubMed ID: 33232734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute Kidney Injury Risk in Patients Treated with Vancomycin Combined with Meropenem or Cefepime.
    Sussman MS; Mulder MB; Ryon EL; Urrechaga EM; Lama GA; Bahga A; Eidelson SA; Lieberman HM; Schulman CI; Namias N; Proctor KG
    Surg Infect (Larchmt); 2021 May; 22(4):415-420. PubMed ID: 32783764
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.